TMDX stock forecast, quote, news & analysis
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states... Show more
TransMedics Group (TMDX) Stock Analysis: Record Transplant Volume Meets a Margin-Heavy Investment Cycle
Key Takeaways
- TransMedics delivered record third-quarter revenue of roughly $203 million, up 41% year over year and above consensus estimates.
- Adjusted earnings per share of $0.51 exceeded expectations, though GAAP net income declined as research, clinical, and interest expenses climbed.
- Management raised full-year 2026 revenue guidance to $764–$774 million, implying approximately 26%–28% growth.
- Shares are roughly 9% higher over the trailing 30 days despite a volatile path that included a late-October sell-off followed by a sharp post-earnings rebound.
- Gross margin pressure persists as the company invests in OCS Kidney, next-generation OCS, and its ENHANCE and DENOVO clinical programs.
- The FDA cleared key trial amendments, and the company won its first European transplant logistics tender in Italy, supporting a 2027 catalyst pipeline.
- For additional detail, explore TransMedics Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic ideas can also explore Trending AI Robots, which highlights top-performing AI-driven strategies.
Current Market Snapshot
TransMedics Group (NASDAQ: TMDX) sits at the intersection of medical technology and organ transplantation, a niche that has drawn steady investor attention because of its limited competition and large addressable market. Over the trailing 30 days, the stock has moved from about $81 to roughly $88, but that headline masks meaningful volatility. Shares weakened through much of October before rallying sharply after the company reported third-quarter results, as revenue reaccelerated and guidance was raised. The stock trades with above-average volatility typical of high-growth medtech names, with sentiment closely tied to quarterly case volumes, margin trajectory, and clinical-trial milestones rather than broad market rotation alone.
TransMedics Group (TMDX) Business Overview and Competitive Position
TransMedics Group is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage heart, lung, and liver failure. Its core platform, the Organ Care System (OCS), is a portable system that uses warm perfusion to keep donor organs functioning in near-physiologic conditions outside the body, replacing traditional cold storage. The OCS is the only FDA-approved portable warm-perfusion platform covering heart, lung, and liver transplants, which gives the company a differentiated position in a market with limited direct competition.
Beyond the device itself, TransMedics operates the National OCS Program (NOP), a turnkey service offering outsourced organ procurement, perfusion management, and transplant logistics, including aviation transport through its PAD Aviation business. This integrated model allows the company to capture both product and service revenue, deepening its relationship with transplant centers while expanding its total addressable opportunity. Investors follow TMDX for its combination of organic case-volume growth, international expansion, and a clinical pipeline aimed at broadening indications in heart and lung transplantation.
Recent Developments Driving TMDX
The most significant recent catalyst was the company's third-quarter 2026 earnings release, which showed total revenue of about $203 million, up 41% year over year and the strongest quarter in the company's history. Product revenue rose 29% to roughly $113 million, while service revenue climbed 60% to about $90 million. International revenue increased 82%, and liver and heart case volumes grew sequentially despite a 6% decline in overall U.S. deceased donor volume, signaling market-share gains.
Adjusted earnings per share of $0.51 beat consensus estimates by a wide margin, and management raised full-year 2026 revenue guidance to $764–$774 million. However, the quarter also highlighted the cost of growth: gross margin slipped to 58.5%, research and development spending nearly doubled, and interest expense rose as new lease obligations were added. GAAP net income fell year over year even as operating income grew. On the clinical front, the FDA approved protocol amendments adding the company's CHOPS system as a control arm in the ENHANCE Heart Part B and DENOVO Lung trials, and TransMedics won its first European transplant logistics tender in Italy. Analyst responses were mixed, with Hold ratings from firms including Oppenheimer and J.P. Morgan alongside a Buy rating from Canaccord Genuity.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a broader universe of hundreds of strategies that collectively monitor thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a filtered view of systematic approaches that are currently standing out. The bots vary in trading strategy, timeframe, and performance metrics, so investors can compare different styles rather than relying on a single method. For those interested in complementing their own research with data-driven, algorithm-based signals, the page offers a practical starting point for exploring automated trading ideas.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape the TMDX investment case. The ENHANCE Heart Part B and DENOVO Lung programs are expected to become meaningful catalysts beginning in early 2027, with the potential to expand the company's addressable heart and lung transplant populations. OCS Kidney development is progressing toward clinical testing in 2027, representing a longer-term growth opportunity. International expansion, supported by aviation infrastructure and logistics hubs in Europe, is another key driver.
On the financial side, investors will monitor whether revenue growth can translate into margin improvement as the company works through its investment cycle. Management has guided to adjusted operating margins of 12.5%–14% for 2026 and has not yet reiterated longer-term margin targets. Rising interest expense, service gross-margin normalization, and the timing of clinical-trial revenue are additional considerations. Macroeconomic and regulatory factors affecting transplant volumes, donor supply, and reimbursement also remain relevant to the outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TMDX turns positive, indicating new upward trend
TMDX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 76 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMDX just turned positive on November 04, 2026. Looking at past instances where TMDX's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
TMDX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +35.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in 254 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
TMDX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TMDX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. TMDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.906) is normal, around the industry mean (4.142). P/E Ratio (19.829) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.709) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.033) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of a proprietary system for preserving human organs for transplant
Industry MedicalNursingServices